Celcuity Inc.(CELC)

Sector:

Healthcare

Description:

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Current Price

$11.06

RSI

61.82

Market Capitalization:

142M

Beta:

1.541

Volume:

47,181

Analyst Target Price:

$ 43.75

Economiic Fair Price:


November 14, 2022
November 10, 2022
Q3
N/A
N/A
N/A
N/A
N/A
57.5M
306389
-2.079
N/A
0
-0.576

$ -89.6K
98.76 %
$ -7.2M
-13.42 %
$ -6.4M
4.88 %
$ -6.7M
-29.26 %
$ -5.2M
-77.11 %
$ -2.9M

News

Press Releases

Notable Dates